Nouvelles approches thérapeutiques de l’inflammation et de la progression dans la sclérose en plaques (évaluations cliniques et IRM)

Lublin, 2014, Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology, 83, 278, 10.1212/WNL.0000000000000560 Magliozzi, 2017, Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology, Brain, 130, 1089, 10.1093/brain/awm038 Lassmann, 2007, The immunopathology of multiple sclerosis: an overview, Brain Pathol, 17, 210, 10.1111/j.1750-3639.2007.00064.x Hauser, 2017, Ocrelizumab versus interferon beta1a in relapsing multiple sclerosis, N Engl J Med, 376, 221, 10.1056/NEJMoa1601277 Hauser, 2018, Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis, ECTRIMSBerlin Montalban, 2018, Primary analysis of a randomised, placebo-controlled, phase 2 study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis, ECTRIMS Berlin Giovannoni G. https://www.excemed.org/resources/how-transfer-concept-clinical-practice. [Accessed July 2017] Mancardi, 2008, Autologous haematopoietic stem-cell transplantation in multiple sclerosis, Lancet Neurol, 7, 626, 10.1016/S1474-4422(08)70138-8 Baker, 2017, Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab, JAMA Neurol, 74, 961, 10.1001/jamaneurol.2017.0676 Baker, 2017, Both cladribine and alemtuzumab may effect MS via B-cell depletion, Neurol Neuroimmunol Neuroinflamm, 4, e360, 10.1212/NXI.0000000000000360 Giovannoni, 2017, Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients studies in the CLARITY and CLARITY EXTENSION studies, CMSC Montalban, 2017, Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, New Engl J Med, 376, 209, 10.1056/NEJMoa1606468 Tourbah, 2016, MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study, Multiple Sclerosis J, 22, 1719, 10.1177/1352458516667568 Cadavid, 2014 Mei, 2014, Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis, Nat Med, 20, 954, 10.1038/nm.3618 Green, 2018, Promoting endogenous remyelination: from basic sciences to translation, ECTRIMS Berlin Hartung, 2018, Week 48 results from a phase IIb trial of GNbAC1 in patients with relapsing remitting multiple sclerosis (CHANGE-MS; clinical trial assessing the HERV-W Env antagonist GNbAC1 for Efficacy in MS), ECTRIMS Berlin Fox, 2018, Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis, N Engl J Med, 379, 846, 10.1056/NEJMoa1803583 Chataway, 2018, Trial MS-SMART. A multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [NCT01910259], ECTRIMS Berlin